REG - IXICO plc - c.£1.5 million Contract Extension

IXICOAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260212:nRSL6752Sa&default-theme=true

RNS Number : 6752S  IXICO plc  12 February 2026

IXICO plc

("IXICO", the "Company" or the "Group")

 

c.£1.5 million contract extension on global Phase 2 clinical trial

 

 

12 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader
in neuroscience imaging and biomarker analytics, using its AI-driven platform
to help advance drug development in neurological disorders, today announced
the extension of an existing contract with one of the world's leading
international pharmaceutical companies following the continued progress of a
Phase 2 clinical trial in Huntington's Disease.

 

The contract extension is worth an additional c.£1.5 million in revenues to
IXICO over the next three years.

 

Bram Goorden, CEO of IXICO, commented: "Thanks to this contract extension
IXICO has secured over £2.7m in new revenues with 2 existing clients in the
last 2 months.  This is another example of how IXICO's compelling IXI™
technology platform and neurological disease expertise consistently deliver
gold standard outcomes for biopharma customers as they advance drug
development in such a devastating neurological disease."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

 

Ends

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFFEFFEMSEFE



            Copyright 2019 Regulatory News Service, all rights reserved